Biocartis Group NV
XBRU:BCART
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (2.7), the stock would be worth €0.29 (0% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.7 | €0.29 |
0%
|
| 3-Year Average | 2.7 | €0.29 |
0%
|
| 5-Year Average | 2.7 | €0.29 |
0%
|
| Industry Average | 2.2 | €0.23 |
-19%
|
| Country Average | 1.8 | €0.2 |
-33%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
€161.3m
|
/ |
Jul 2023
€60.6m
|
= |
|
|
€161.3m
|
/ |
Dec 2023
€59.7m
|
= |
|
|
€161.3m
|
/ |
Dec 2024
€78.3m
|
= |
|
|
€161.3m
|
/ |
Dec 2025
€103m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| BE |
|
Biocartis Group NV
XBRU:BCART
|
27.3m EUR | 2.7 | -0.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 15.8 | 57.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 3.6 | 25.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 5.3 | 37.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 3.5 | 22.7 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 4.6 | 24.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7 | 43.4 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 2 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 10.6 | 42.9 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 2.7 | 24 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 5.6 | 21.2 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 1.1 |
| Median | 1.8 |
| 70th Percentile | 5.5 |
| Max | 217.1 |
Other Multiples
Biocartis Group NV
Glance View
Biocartis Group NV which engages in the development of oncology molecular diagnostic solutions. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 619 full-time employees. The company went IPO on 2015-04-27. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
